258 related articles for article (PubMed ID: 2645844)
1. The drug approval process at the Food and Drug Administration. New biotechnology as a paradigm of a science-based activist approach.
Miller HI; Young FE
Arch Intern Med; 1989 Mar; 149(3):655-7. PubMed ID: 2645844
[No Abstract] [Full Text] [Related]
2. FDA perspective on specifications for biotechnology products--from IND to PLA.
Murano G
Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
[TBL] [Abstract][Full Text] [Related]
3. How FDA approves biotechnology drugs.
Manuel SM; Piascik P
Am Pharm; 1995 May; NS35(5):14-5. PubMed ID: 7611131
[No Abstract] [Full Text] [Related]
4. Is the drought over for pharming?
Kaiser J
Science; 2008 Apr; 320(5875):473-5. PubMed ID: 18436771
[No Abstract] [Full Text] [Related]
5. Biogenerics standoff.
Herrera S
Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
[No Abstract] [Full Text] [Related]
6. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
Koivuniemi PJ
Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
[No Abstract] [Full Text] [Related]
7. Trials and error.
Jacobs T
Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
[No Abstract] [Full Text] [Related]
8. The FDA's drug review process: ensuring drugs are safe and effective.
Meadows M
FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
[No Abstract] [Full Text] [Related]
9. King of the pill. Pfizer is the biggest drug company ever. Can it become the best?
Simons J
Fortune; 2003 Apr; 147(7):94-6, 100, 102. PubMed ID: 12698860
[No Abstract] [Full Text] [Related]
10. BIO and biogenerics.
Feldbaum CB
Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
[No Abstract] [Full Text] [Related]
11. FDA and EMEA pool scientific advice.
Katsnelson A
Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
[No Abstract] [Full Text] [Related]
12. Investing in risk management.
Fiscus PW
Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
[No Abstract] [Full Text] [Related]
13. The special treatment.
Osborne R
Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
[No Abstract] [Full Text] [Related]
14. A proposal for radical changes in the drug-approval process.
Wood AJ
N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784
[No Abstract] [Full Text] [Related]
15. FDA scrutinizes human stem cell therapies.
Fox JL
Nat Biotechnol; 2008 Jun; 26(6):598-9. PubMed ID: 18536668
[No Abstract] [Full Text] [Related]
16. Shared responsibility in clinical research.
Nightingale SL
Circulation; 1985 Aug; 72(2 Pt 2):I25-30. PubMed ID: 3891137
[No Abstract] [Full Text] [Related]
17. Trouble at the office.
Allison M
Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
[No Abstract] [Full Text] [Related]
18. Biotechnology drugs create new maze of concerns for hospitals.
Lumsdon K
Hospitals; 1991 Dec; 65(23):32, 34-5. PubMed ID: 1937456
[TBL] [Abstract][Full Text] [Related]
19. Drug development process for a product with a primary pediatric indication.
Allen AJ; Michelson D
J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
[TBL] [Abstract][Full Text] [Related]
20. Advancing TB vaccines to Phase I clinical trials in the US: regulatory/manufacturing/licensing issues.
Rowland SS; Mayner RL; Barker L
Tuberculosis (Edinb); 2005; 85(1-2):39-46. PubMed ID: 15687026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
